Zhongxin Jingwei, April 18 -- After the market on the 18th, Qizheng Tibetan Medicine released its 2023 annual report.
Screenshot of Qizheng Tibetan Medicine's 2023 annual report
According to the annual report data, in 2023, Qizheng Tibetan Medicine will achieve operating income of 2.045 billion yuan, an increase of 0.02% year-on-year, net profit attributable to shareholders of listed companies (hereinafter referred to as "net profit") of 581 million yuan, an increase of 22.99% year-on-year, and net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses (hereinafter referred to as "non-net profit") of 370 million yuan, a year-on-year decrease of 15.94%.
Screenshot of Qizheng Tibetan Medicine's 2023 annual performance report
Zhongxin Jingwei noted that the net profit and non-net profit of Qizheng Tibetan Medicine in 2023 are lower than the data published in the 2023 performance express report. According to the performance express report, the net profit for the current period was 612 million yuan, an increase of 29.49% year-on-year, and the non-net profit was 400 million yuan, a year-on-year decrease of 9.02%.
Qizheng Tibetan Medicine mentioned in the performance express report that the increase in net profit was mainly due to the increase in non-recurring profit and loss over the same period last year. At the same time, it is noted that there may be discrepancies with the final data disclosed in the annual report.
According to the annual report, the main business of Qizheng Tibetan Medicine is the research and development, production and sales of Tibetan medicine, including external painkillers and oral Tibetan medicines, traditional Chinese medicines, etc.
In terms of products, the operating income of plaster was 1.423 billion yuan, an increase of 0.50% year-on-year, the gross profit margin was 86.54%, and the gross profit margin decreased by 0.17 percentage points over the same period of last year, the operating income of ointment was 285 million yuan, a year-on-year decrease of 7.56%, the gross profit margin was 87.03%, and the gross profit margin increased by 3.82 percentage points over the same period of last year, and the operating income of other dosage forms was 318 million yuan, an increase of 4.90% year-on-year, and the gross profit margin was 75.32% The gross profit margin decreased by 0.93 percentage points over the same period of last year, the operating income of health care products was 214,100 yuan, a year-on-year decrease of 94.32%, the gross profit margin was 4.53%, and the gross profit margin decreased by 40.25 percentage points over the same period of last year; the operating income of other products was 19.5954 million yuan, an increase of 37.77% year-on-year, the gross profit margin was 16.98%, and the gross profit margin decreased by 10.95 percentage points over the same period of last year.
In terms of profit distribution, Qizheng Tibetan Medicine plans to distribute a cash dividend of 4.8 yuan (tax included) to all shareholders for every 10 shares.
In the secondary market, Qizheng Tibetan Medicine closed down 0.14% at 21.36 yuan per share on the 18th, with a total market value of 11.3 billion yuan. (Sino-Singapore Jingwei APP)